448 related articles for article (PubMed ID: 25483423)
1. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
Ye J; Shin MC; Liang Q; He H; Yang VC
J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
[TBL] [Abstract][Full Text] [Related]
2. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
[TBL] [Abstract][Full Text] [Related]
3. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery.
Huang Y; Park YS; Wang J; Moon C; Kwon YM; Chung HS; Park YJ; Yang VC
Curr Pharm Des; 2010 Jul; 16(21):2369-76. PubMed ID: 20618157
[TBL] [Abstract][Full Text] [Related]
4. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
[TBL] [Abstract][Full Text] [Related]
5. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
6. pH-Sensitive nanoparticles as smart carriers for selective intracellular drug delivery to tumor.
Li XX; Chen J; Shen JM; Zhuang R; Zhang SQ; Zhu ZY; Ma JB
Int J Pharm; 2018 Jul; 545(1-2):274-285. PubMed ID: 29733971
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
8. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
[TBL] [Abstract][Full Text] [Related]
9. Intracellular delivery of nanoparticles with CPPs.
Sawant R; Torchilin V
Methods Mol Biol; 2011; 683():431-51. PubMed ID: 21053148
[TBL] [Abstract][Full Text] [Related]
10. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
[TBL] [Abstract][Full Text] [Related]
11. The ATTEMPTS delivery systems for macromolecular drugs.
Kwon YM; Li Y; Naik S; Liang JF; Huang Y; Park YJ; Yang VC
Expert Opin Drug Deliv; 2008 Nov; 5(11):1255-66. PubMed ID: 18976135
[TBL] [Abstract][Full Text] [Related]
12. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.
Kwon YM; Li YT; Liang JF; Park YJ; Chang LC; Yang VC
J Control Release; 2008 Sep; 130(3):252-8. PubMed ID: 18652856
[TBL] [Abstract][Full Text] [Related]
13. Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy.
Wang H; Moon C; Shin MC; Wang Y; He H; Yang VC; Huang Y
Nanotheranostics; 2017; 1(1):114-130. PubMed ID: 29071181
[TBL] [Abstract][Full Text] [Related]
14. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading.
Chen Z; Zhang P; Cheetham AG; Moon JH; Moxley JW; Lin YA; Cui H
J Control Release; 2014 Oct; 191():123-30. PubMed ID: 24892976
[TBL] [Abstract][Full Text] [Related]
15. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment.
Duong HH; Yung LY
Int J Pharm; 2013 Sep; 454(1):486-95. PubMed ID: 23792465
[TBL] [Abstract][Full Text] [Related]
16. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
17. Improved Protein Toxin Delivery Based on ATTEMPTS Systems.
Chen Y; Zhang M; Min KA; Wang H; Shin MC; Li F; Yang VC; Huang Y
Curr Drug Targets; 2018 Feb; 19(4):380-392. PubMed ID: 28260497
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents.
He H; Sun L; Ye J; Liu E; Chen S; Liang Q; Shin MC; Yang VC
J Control Release; 2016 Oct; 240():67-76. PubMed ID: 26514292
[TBL] [Abstract][Full Text] [Related]
19. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.
Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL
Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028
[TBL] [Abstract][Full Text] [Related]
20. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
